Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Multiple Myeloma (US)

Articles with lock require a subscription to GLG News | Request a free trial
December 1, 2008
Avastin Raises Risk of Clots: New News?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
November 24, 2008
Avastin and clots? News to me. Black box warning? Why?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: GLG Expert Contributor
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
November 24, 2008
GSK's Promacta for ITP: a winner1
Analysis of: PROMACTA (Brand Name Drug) FDA approval 11/20/08 | www.accessdata.fda.gov
Author: GLG Expert Contributor
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
November 19, 2008
Vandetanib (Astra Zeneca): too long at the "Fair?"
Analysis of: Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
November 17, 2008
Erbitux in Lung Ca- now to predict who will get the skin rash.
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: GLG Expert Contributor
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...
November 11, 2008
Roche's Tarceva offers a competitor to Lilly's Alimta
Analysis of: Roche Says Tarceva Data Promising | online.wsj.com
Author: GLG Expert Contributor
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
November 11, 2008
Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
Analysis of: Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma | jco.ascopubs.org
Author: GLG Expert Contributor
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.
November 10, 2008
Big Pharma will continue to thrive in new administration, but not insurnace companies
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
President elect Obama will try , most probably unsuccessfully, to take on insurance companies in orfder to fulfill his election promises of "close to universal" health care. Generics will thrive, but Big Phrama , especially those with innovative products and biotech companies will continue to pr...
November 10, 2008
Rainfall unlikely to be direct culprit to the Autism Pandemic
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
A recent study infers taht periods of increased rainfall could be linked to increase in number of children dioagnosed with autism. The causla l;ink of rainfall is unlikely, but most probably reflects other factors like children staying more indoors and thus watch more TV, get less sun exposure and...
November 10, 2008
Avastin for GBM: modest efficacy and soon to be approval
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech's Avastin have shown modest increase in progresion free survival and overall survival in patients with gliobalstoma multiforme, the most common and most agressive malignant brain tumor With such data, Avastin is expected to join Temodar as chemotherapy agent approved for this tumor with...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 769

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637